Login Register Cart 0
Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

In vitro and in vivo Assessment of Silver Nanoparticles Against Clostridium botulinum Type A Botulinum

Author(s): Mohammad Aminianfar, Siavash Parvardeh and Mohsen Soleimani*

Volume 16, Issue 1, 2019

Page: [113 - 119] Pages: 7

DOI: 10.2174/1570163815666180403163946

Price: $65

Abstract

Background: Clostridium botulinum causes botulism, a serious paralytic illness that results from the ingestion of a botulinum toxin. Because silver nanoparticle products exhibit strong antimicrobial activity, applications for silver nanoparticles in healthcare have expanded. Therefore, the objective of the current study was to assess a therapeutic strategy for the treatment of botulism toxicity using silver nanoparticles.

Methods: A preliminary test was conducted using doses that produce illness in laboratory animals to determine the absolute lethal dose (LD100) of botulinum toxin type A (BoNT/A) in mice. Next, the test animals were divided into six groups containing six mice each. Groups I, II and III were the negative control (botulinum toxin only), positive control-1 (nano-silver only) and positive control-2 (no treatment), respectively. The remaining groups were allocated to the toxin that was supplemented with three nano-silver treatments.

Results: The mortality rates of mice caused by BoNT/A significantly reduced in the treatment groups with different doses and injection intervals of nano-silver when compared to the negative control group. BoNT/A toxicity induced by intraperitoneal injection of the toxin of Clostridium botulinum causes rapid death while when coupled with nano-osilver results in delayed death in mice.

Conclusion: These results, while open to future improvement, represent a preliminary step towards the satisfactory control of BoNT/A with the use of silver nanoparticles for human protection against this bioterrorism threat. Further study in this area can elucidate the underlying mechanism for detoxifying BoNT/A by silver nanoparticles.

Keywords: Antibacterial, Clostridium botulinum, botulism, BoNT/A toxin, intoxication, nano-silver.

Graphical Abstract

[1]
Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: Genetic, structural and mechanistic insights. Nat Rev Microbiol 2014; 12: 535-49.
[2]
Rust A, Leese C, Binz T, Davletov B. Botulinum neurotoxin type C protease induces apoptosis in differentiated human neuroblastoma cells. Oncotarget 2016; 7: 33220-8.
[3]
Pirazzini M, Rossetto O, Eleopra R, Montecucco C. Botulinum neurotoxins: Biology, pharmacology, and toxicology. Pharmacol Rev 2017; 69: 200-35.
[4]
Deitiker P, Oshima M, Jankovic J, Atassi MZ. Influences of HLA DRB1, DQA1 and DQB1 on T-cell recognition of epitopes and of larger regions of the botulinum neurotoxin molecule. Immunol Lett 2017; 190: 257-64.
[5]
Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: Medical and public health management. JAMA 2001; 285: 1059-70.
[6]
Johnson EA, Bradshaw M. Clostridium botulinum and its neurotoxins: A metabolic and cellular perspective. Toxicon 2001; 39: 1703-22.
[7]
Bhardwaj T, Somvanshi P. Pan-genome analysis of Clostridium botulinum reveals unique targets for drug development. Gene 2017; 623: 48-62.
[8]
Tsai YC, Maditz R, Kuo CL, et al. Targeting botulinum neurotoxin persistence by the ubiquitin-proteasome system. Proc Natl Acad Sci USA 2010; 107: 16554-9.
[9]
Kvitek L, Panáček A, Soukupova J, et al. Effect of surfactants and polymers on stability and antibacterial activity of Silver Nanoparticles (NPs). J Phys Chem 2008; 112: 5825-34.
[10]
Chen X, Schluesener HJ. Nanosilver: A nanoproduct in medical application. Toxicol Lett 2008; 176: 1-12.
[11]
Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv 2009; 27: 76-83.
[12]
Xie P, Ji W, Wei Z. Preparation and properties of silver nanoparticlesCharacter Appl Nanomater 1: 40-8
[13]
El-Naggar NEA, Hussein MH, El-Sawah AA. Bio-fabrication of silver nanoparticles by phycocyanin, characterization, in vitro anticancer activity against breast cancer cell line and in vivo cytotoxicity. Sci Rep 2017; 7: 10844.
[14]
Goudarzi M, Mir N, Mousavi-Kamazani M, Bagheri S. Salavati-Niasari. Biosynthesis and characterization of silver nanoparticles prepared from two novel natural precursors by facile thermal decomposition methods. Sci Rep 2016; 6: 32539.
[15]
Kora AJ, Sashidhar RB. Antibacterial activity of biogenic silver nanoparticles synthesized with gum ghatti and gum olibanum: A comparative study. J Antibiot 2015; 68: 88-97.
[16]
Tareq FK, Fayzunnesa M, Kabir MS, Nuzat M. Mechanism of bio molecule stabilized selenium nanoparticles against oxidation process and Clostridium botulinum. Microb Pathog 2018 in press
[http://dx.doi.org/10.1016/j.micpath.2017.12.042]
[17]
Ema M, Okuda H, Gamo M, Honda K. A review of reproductive and developmental toxicity of silver nanoparticles in laboratory animals. Reprod Toxicol 2017; 67: 149-64.
[18]
Yoon KY, Byeon JH, Park JH, Hwang J. Susceptibility constants of Escherichia coli and Bacillus subtilis to silver and copper nanoparticles. Sci Total Environ 2007; 373: 572-5.
[19]
Feng QL, Wu J, Chen GQ, Cui FZ, Kim TN, Kim JO. A mechanistic study of the antibacterial effect of silver ions on Escherichia coli and Staphylococcus aureus. J Biomed Mater Res 2000; 52: 662-8.
[20]
Raffi M, Hussain F, Bhatti TM, Akhter JI, Hameed A, Hasan MM. Antibacterial characterization of silver nanoparticles against E. coli ATCC-15224. J Mater Sci Technol 2008; 24: 192-6.
[21]
Kim JS. Antibacterial activity of Ag+ ion-containing silver nanoparticles prepared using the alcohol reduction method. J Ind Eng Chem 2007; 13: 718-22.
[22]
Popoff MR. Botulinum neurotoxins: Still a privilege of clostridia? Cell Host Microbe 2018; 23: 145-6.
[23]
Chellapandi P, Prisilla A. Clostridium botulinum type A-virulome-gut interactions: A systems biology insight. Human Microb J 2018 in press
[http://dx.doi.org/10.1016/j.humic.2018.01.003]
[24]
Willis B, Eubanks LM, Dickerson TJ, Janda KD. The strange case of the botulinum neurotoxin: Using chemistry and biology to modulate the most deadly poison. Angew Chem Int Ed 2008; 47: 8360-79.
[25]
Al-Saleem FH, Nasser Z, Olson RM, Cao L, Simpson LL. Identification of the factors that govern the ability of therapeutic antibodies to provide postchallenge protection against botulinum toxin: A model for assessing postchallenge efficacy of medical countermeasures against agents of bioterrorism and biological warfare. J Pharmacol Exp Ther 2011; 338: 503-17.
[26]
Harris TL, Lowery CA, Hixon MS, Janda KD. A platform stratifying a sequestering agent and a pharmacological antagonist as a means to negate botulinum neurotoxicity. ACS Chem Neurosci 2014; 5: 632-6.
[27]
Tsai YC, Kotiya A, Kiris E, et al. Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication. Proc Natl Acad Sci USA 2017; 114: E5158-66.
[28]
Jacobson AR, Adler M, Silvaggi NR, et al. Small molecule metalloprotease inhibitor with in vitro, ex vivo and in vivo efficacy against botulinum neurotoxin serotype A. Toxicon 2017; 137: 36-47.
[29]
National Committee for Clinical Laboratory Standards. 2002.Reference method for broth dilution testing of yeast approved standard 22nd ed, Wayne, Pa: National committee for clinical laboratory standards 2002 NCCLS M27-A2.
[30]
Sharma SK, Ramzan MA, Singh BR. Separation of the components of type A botulinum neurotoxin complex by electrophoresis. Toxicon 2003; 41: 321-31.
[31]
Balali-Mood M, Moshiri M, Etemad L. Medical aspects of bio-terrorism. Toxicon 2013; 69: 131-42.
[32]
WHO Fact sheet. Botulism. 2018 http://www.who.int/mediacentre/factsheets/fs270/en/
[33]
Vazquez-Cintron EJ, Ichtchenko K, Band PA. 2016. . Treatment methods using atoxic neurotoxin derivatives. US 20160296608A1 Patents.
[34]
Kumar R, Kukreja RV, Cai S, Singh BR. Differential role of molten globule and protein folding in distinguishing unique features of botulinum neurotoxin. Biochim Biophys Acta 2014; 1844: 1145-52.
[35]
Li WR, Xie XB, Shi QS, Zeng HY, You-Sheng OY, Chen YB. Antibacterial activity and mechanism of silver nanoparticles on Escherichia coli. Appl Microbiol Biotechnol 2010; 85: 1115-22.
[36]
Durán N, Durán M, de Jesus MB, Seabra AB, Fávaro WJ, Nakazato G. Silver nanoparticles: A new view on mechanistic aspects on antimicrobial activity. Nanomed-Nanotechnol 2016; 12: 789-99.
[37]
Arakawa H, Neault JF, Tajmir-Riahi HA. Silver (I) complexes with DNA and RNA studied by Fourier transform infrared spectroscopy and capillary electrophoresis. Biophys J 2001; 81: 1580-7.
[38]
Kudrinskiy AA, Ivanov AY, Kulakovskaya EV. The mode of action of silver and silver halides nanoparticles against Saccharomyces cerevisiae cells. J Nanopart 2014; p. 568635.
[39]
Khadka P, Haque M, Krishnamurthi VR, Niyonshuti I, Chen J, Wang Y. Quantitative investigations reveal new antimicrobial mechanism of silver nanoparticles and ion. Biophys 2018; 114(1): 3690a.
[40]
Lee Y, Kim H, Kim S, et al. The effects of silver and arsenic on antioxidant system in Lemna paucicostata: Different effects on glutathione system. Toxicol Environ Health Sci 2016; 8: 332-40.
[41]
Davies JR, Reesa J, Liu SM, Acharya KR. High resolution crystal structures of Clostridium botulinum neurotoxin A3 and A4 binding domains. J Struct Biol 2018; 202: 113-7.
[42]
Sahaya B, Colliou N, Zadeh M, et al. Dual-route targeted vaccine protects efficiently against botulinum neurotoxin A complex. Vaccine 2018; 36: 155-64.
[43]
McClements DJ, Xiao H. Is nano safe in foods? Establishing the factors impacting the gastrointestinal fate and toxicity of organic and inorganic food-grade nanoparticles. NPJ Sci Food 2017; 1: 6.
[44]
Zaidi S, Misba L, Khan AU. Nano-therapeutics: A revolution in infection control in post antibiotic era. Nanomed- Nanotechnol. Biol Med 2017; 13: 2281-301.
[45]
Soni KS, Desale SS, Bronich TK. Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation. J Control Release 2016; 240: 109-26.
[46]
Panacek A, Kvitek L, Smekalova M, et al. Bacterial resistance to silver nanoparticles and how to overcome it. Nat Nanotechnol 2018; 13: 65-71.

Rights & Permissions Print Cite
Article Metrics
53
6
1
© 2024 Bentham Science Publishers | Privacy Policy